What is the Alivus Life Sciences Ltd share price today?

The share price of NSE:ALIVUS-EQ on 07 Sep 2026 (as of 10:58:46 IST) is ₹1393.00.

What is the NSE:ALIVUS-EQ 52 week high low price?

Over the past 52 weeks (as of 07 Sep 2026), the NSE:ALIVUS-EQ 52 week high low range shows a high of ₹1493.80 and a low of ₹819.00.

What is the Alivus Life Sciences Ltd market cap?

As on 07 Sep 2026, Alivus Life Sciences Ltd market cap is ₹16781.60 Cr.

What is the shareholding pattern of Alivus Life Sciences Ltd Stock?

The shareholding pattern of Alivus Life Sciences Ltd, as of last reported-on 30 Jun 2026 is: Promoters: 74.87% Foreign Institutional Investors (FII): 5.54% Domestic Institutional Investors (DII): 1.53% Mutual Funds: 5.65% Retail & Others: 12.41% This demonstrates an outstanding distribution of ownership.

What are the PE and PB ratios of Alivus Life Sciences Ltd?

The Price-to-Earnings (PE) ratio of Alivus Life Sciences Ltd is 27.83, and the Price-to-Book (PB) ratio is 3.60, as on 07 Sep 2026.

Alivus Life Sciences Share Price

1388.90-11.50 (-0.82%)

+32.60% past 1 Year

Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.

1 Day

-0.82%

1 Week

+0.08%

1 Month

+2.81%

3 Month

+24.44%

6 Month

+41.04%

YTD

+51.53%

1 Year

+32.60%

5 Year

+104.58%

10 Year

Max

+85.19%

YTD

10Y

MAX

Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.

Price Analysis

1 Day

1 Week

1 Month

3 Months

6 Months

1 Year

Low

1388.00

1387.00

1317.60

1086.10

957.00

819.00

High

1422.20

1446.00

1493.80

About

Glenmark Life Sciences Limited is a leading developer and manufacturer of select high value, non-commoditized active pharmaceutical ingredients (APIs) in chronic therapeutic areas, including cardiovascular disease (CVS), central nervous system Read more

Pharmaceuticals & Drugs

Smallcap

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats

1. Premium insight available after login

2. Sign in to view full SWOT analysis

3. Unlock strengths, weaknesses, opportunities & threats

QVT

Quality

0/100-

Valuation

0/100-

Technical

0/100-

Peer Stocks

1 week

1 month

1 year

Name

SUNPHARMANSE

DIVISLABNSE

TORNTPHARMNSE

ZYDUSLIFENSE

CIPLANSE

LAURUSLABSNSE

MANKINDNSE

DRREDDYNSE

AUROPHARMANSE

LUPINNSE

ALIVUSNSE

LTP

1W Low

1W High

Market cap (₹)

1849.8-17.5 (-0.94%)

1832.20

1891.50

4,48,196Cr

9352.5+29.5 (0.32%)

9315.50

9461.50

2,50,390Cr

4925.5+50.5 (1.04%)

4827

4986.50

1,88,967Cr

1167.1+32 (2.82%)

1147.70

1178

1,15,860Cr

1375.6-0.7 (-0.05%)

1364.50

1405.20

1,11,888Cr

2011.3+63.2 (3.24%)

1954

2032.80

1,09,035Cr

2482.2+182.2 (7.92%)

2287.70

2490

1,00,364Cr

1213.3+38.3 (3.26%)

1182.10

1222

1,00,329Cr

1696.9+6.9 (0.41%)

1676.10

1738.90

98,804Cr

2120.3+22.2 (1.06%)

2075

2130

96,940Cr

1388.9+1.1 (0.08%)

1387

1446

17,196Cr

Alivus Life Sciences Share Price

1388.90-11.50 (-0.82%)

+32.60% past 1 Year

Financial overview

Compounded Sales Growth

10 years-

5 years6%

3 years6%

Last year7%

Compounded Profit Growth

10 years-

5 years10%

3 years7%

Last year16%

Stock Price CAGR

10 years-

5 years16%

3 years31%

1 year34%

Return on Equity

10 years83%

5 years22%

3 years19%

Last year18%

CAGR%

Sales

Profits

Returns

ROE

10Y	5Y	3Y	TTM
-	6%	6%	7%
-	10%	7%	16%
-	16%	31%	34%
83%	22%	19%	18%

Peer Comparison

Symbol

SUNPHARMA

DIVISLAB

TORNTPHARM

ZYDUSLIFE

CIPLA

LAURUSLABS

MANKIND

DRREDDY

AUROPHARMA

LUPIN

ALIVUS

Price	M.Cap (₹)	PE Ratio	EPS (₹)	EV/EBITDA	Annual PAT
1,849.8	₹448196 Cr	37.05	12.07	62.82	₹11479 Cr
9,352.5	₹250390 Cr	85.6	34.04	128.41	₹2568 Cr
4,925.5	₹188967 Cr	86.64	16.72	97.06	₹2163 Cr
1,167.1	₹115860 Cr	25.67	9.42	62.53	₹5040 Cr
1,375.6	₹111888 Cr	33.19	9.77	57.87	₹3879 Cr
2,011.3	₹109035 Cr	99.72	6.8	29.25	₹889 Cr
2,482	₹100364 Cr	49.13	13.75	71.08	₹1913 Cr
1,213.3	₹100329 Cr	31.14	5.32	63.99	₹4196 Cr
1,696.9	₹98804 Cr	26.61	17.95	96.84	₹3505 Cr
2,120.3	₹96940 Cr	17.53	30.95	154.36	₹5333 Cr
1,388.9	₹17196 Cr	28.52	13.04	55.54	₹564 Cr

Profit & Loss

Consolidated

Standalone

Quarterly

Yearly

₹

Name

Net Revenue

Other Income

Total Revenue

Total Expenditure

Operating Profit

Interest Expense

PBT

Net Profit

Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023	Jun 2023	Mar 2023	Dec 2022	Sep 2022	Jun 2022	Mar 2022	Dec 2021	Sep 2021	Jun 2021	Mar 2021	Dec 2020	Sep 2020	Jun 2020
₹640 Cr	₹689 Cr	₹673 Cr	₹588 Cr	₹602 Cr	₹650 Cr	₹642 Cr	₹507 Cr	₹589 Cr	₹537 Cr	₹573 Cr	₹595 Cr	₹578 Cr	₹621 Cr	₹541 Cr	₹509 Cr	₹490 Cr	₹514 Cr	₹522 Cr	₹562 Cr	₹525 Cr	₹467 Cr	₹500 Cr	₹521 Cr	₹397 Cr
₹22 Cr	₹23 Cr	₹14 Cr	₹15 Cr	₹9 Cr	₹10 Cr	₹10 Cr	₹9 Cr	₹5 Cr	₹3 Cr	₹2 Cr	₹5 Cr	₹2 Cr	₹3 Cr	₹7 Cr	₹10 Cr	₹9 Cr	₹5 Cr	₹4 Cr	₹2 Cr	₹4 Cr	₹34 L	₹37 L	₹1 L	₹2 Cr
₹663 Cr	₹712 Cr	₹687 Cr	₹603 Cr	₹611 Cr	₹660 Cr	₹652 Cr	₹515 Cr	₹594 Cr	₹540 Cr	₹574 Cr	₹601 Cr	₹580 Cr	₹624 Cr	₹547 Cr	₹519 Cr	₹499 Cr	₹519 Cr	₹526 Cr	₹564 Cr	₹529 Cr	₹468 Cr	₹501 Cr	₹521 Cr	₹399 Cr
₹449 Cr	₹495 Cr	₹461 Cr	₹427 Cr	₹447 Cr	₹467 Cr	₹467 Cr	₹388 Cr	₹444 Cr	₹410 Cr	₹413 Cr	₹441 Cr	₹398 Cr	₹426 Cr	₹406 Cr	₹376 Cr	₹353 Cr	₹381 Cr	₹386 Cr	₹404 Cr	₹373 Cr	₹306 Cr	₹354 Cr	₹402 Cr	₹267 Cr
₹234 Cr	₹237 Cr	₹245 Cr	₹194 Cr	₹181 Cr	₹209 Cr	₹201 Cr	₹143 Cr	₹165 Cr	₹145 Cr	₹174 Cr	₹172 Cr	₹195 Cr	₹209 Cr	₹152 Cr	₹154 Cr	₹156 Cr	₹147 Cr	₹150 Cr	₹169 Cr	₹164 Cr	₹170 Cr	₹155 Cr	₹127 Cr	₹140 Cr
₹1 Cr	₹1 Cr	₹1 Cr	₹1 Cr	₹1 Cr	₹1 Cr	₹46 L	₹34 L	₹35 L	₹36 L	₹39 L	₹40 L	₹40 L	₹12 L	₹16 L	₹13 L	₹14 L	₹13 L	₹6 L	₹7 Cr	₹21 Cr	₹21 Cr	₹22 Cr	₹22 Cr	₹23 Cr
₹212 Cr	₹216 Cr	₹198 Cr	₹174 Cr	₹163 Cr	₹191 Cr	₹185 Cr	₹127 Cr	₹150 Cr	₹130 Cr	₹161 Cr	₹159 Cr	₹182 Cr	₹198 Cr	₹141 Cr	₹144 Cr	₹146 Cr	₹138 Cr	₹140 Cr	₹153 Cr	₹135 Cr	₹141 Cr	₹125 Cr	₹97 Cr	₹108 Cr
₹160 Cr	₹163 Cr	₹150 Cr	₹130 Cr	₹122 Cr	₹142 Cr	₹137 Cr	₹95 Cr	₹111 Cr	₹98 Cr	₹119 Cr	₹119 Cr	₹135 Cr	₹146 Cr	₹105 Cr	₹107 Cr	₹109 Cr	₹99 Cr	₹104 Cr	₹115 Cr	₹101 Cr	₹105 Cr	₹93 Cr	₹72 Cr	₹81 Cr

Balance Sheet

Consolidated

Standalone

₹

Name

Equity And Liabilities

Share Capital

Share Warrants & Outstandings

Total Reserves

Reserve excluding Revaluation Reserve

Shareholder's Funds

Deferred Tax Assets / Liabilities

Other Long Term Liabilities

Long Term Provisions

Total Non-Current Liabilities

Current Liabilities

Trade Payables

Other Current Liabilities

Short Term Borrowings

Short Term Provisions

Total Current Liabilities

Total Liabilities

Contingent Liabilities

Total Debt

Assets

Gross Block

Less Accumulated Depreciation

Net Block

Capital Work in Progress

Non Current Investments

Long Term Investment

Long Term Loans & Advances

Total Non-Current Assets

Current Assets Loans & Advances

Currents Investments

Inventories

Sundry Debtors

Cash and Bank

Other Current Assets

Short Term Loans and Advances

Total Current Assets

Net Current Assets (Including Current Investments)

Total Assets

Book Value

Adjusted Book Value

Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020	Mar 2019	Mar 2018
—	—	—	—	—	—	—	—	—
₹25 Cr	₹25 Cr	₹25 Cr	₹25 Cr	₹25 Cr	₹2 Cr	₹2 Cr	₹2 Cr	₹1 L
₹7 Cr	₹10 Cr	₹11 Cr	₹7 Cr	₹3 Cr	₹0	₹0	₹0	₹0
₹3300 Cr	₹2783 Cr	₹2297 Cr	₹2107 Cr	₹2026 Cr	₹751 Cr	₹400 Cr	₹86 Cr	-₹1 Cr
₹3300 Cr	₹2783 Cr	₹2297 Cr	₹2107 Cr	₹2026 Cr	₹751 Cr	₹400 Cr	₹86 Cr	-₹1 Cr
₹3332 Cr	₹2817 Cr	₹2332 Cr	₹2138 Cr	₹2054 Cr	₹753 Cr	₹402 Cr	₹88 Cr	-₹1 Cr
₹58 Cr	₹54 Cr	₹49 Cr	₹42 Cr	₹31 Cr	₹23 Cr	₹16 Cr	₹7 Cr	₹0
₹49 Cr	₹51 Cr	₹15 Cr	₹17 Cr	₹1 Cr	₹0	₹0	₹0	₹0
₹36 Cr	₹361 Cr	₹693 Cr	₹8 Cr	₹0	₹0	₹0	₹0	₹0
₹143 Cr	₹466 Cr	₹757 Cr	₹67 Cr	₹33 Cr	₹23 Cr	₹16 Cr	₹7 Cr	₹0
—	—	—	—	—	—	—	—	—
₹372 Cr	₹390 Cr	₹369 Cr	₹427 Cr	₹308 Cr	₹221 Cr	₹201 Cr	₹183 Cr	₹1 L
₹99 Cr	₹63 Cr	₹58 Cr	₹55 Cr	₹50 Cr	₹967 Cr	₹1084 Cr	₹1181 Cr	₹1 Cr
₹0	₹0	₹0	₹0	₹0	₹0	₹2 L	₹2 L	₹0
₹211 Cr	₹17 Cr	₹12 Cr	₹533 Cr	₹389 Cr	₹257 Cr	₹22 Cr	₹16 Cr	₹1 L
₹682 Cr	₹470 Cr	₹439 Cr	₹1015 Cr	₹747 Cr	₹1445 Cr	₹1307 Cr	₹1380 Cr	₹1 Cr
₹4157 Cr	₹3754 Cr	₹3528 Cr	₹3220 Cr	₹2834 Cr	₹2221 Cr	₹1726 Cr	₹1475 Cr	₹9 L
₹5 Cr	₹5 Cr	₹5 Cr	₹2 Cr	₹2 Cr	₹2 Cr	₹2 Cr	₹3 Cr	₹0
₹0	₹0	₹0	₹0	₹0	₹0	₹2 L	₹2 L	₹0
—	—	—	—	—	—	—	—	—
₹1367 Cr	₹1219 Cr	₹1012 Cr	₹936 Cr	₹706 Cr	₹652 Cr	₹595 Cr	₹476 Cr	₹10,000
₹329 Cr	₹264 Cr	₹207 Cr	₹156 Cr	₹116 Cr	₹79 Cr	₹49 Cr	₹19 Cr	₹0
₹1038 Cr	₹955 Cr	₹805 Cr	₹781 Cr	₹590 Cr	₹573 Cr	₹546 Cr	₹456 Cr	₹10,000
₹273 Cr	₹94 Cr	₹101 Cr	₹49 Cr	₹92 Cr	₹14 Cr	₹11 Cr	₹80 Cr	₹0
₹8 L	₹8 L	₹8 L	₹8 L	₹8 L	₹8 L	₹8 L	₹8 L	₹0
₹8 L	₹8 L	₹8 L	₹8 L	₹8 L	₹8 L	₹8 L	₹8 L	₹0
₹12 Cr	₹361 Cr	₹701 Cr	₹9 Cr	₹20 Cr	₹11 Cr	₹8 Cr	₹8 Cr	₹0
₹1334 Cr	₹1418 Cr	₹1612 Cr	₹852 Cr	₹706 Cr	₹598 Cr	₹565 Cr	₹545 Cr	₹10,000
—	—	—	—	—	—	—	—	—
₹780 Cr	₹478 Cr	₹0	₹0	₹0	₹0	₹0	₹0	₹0
₹692 Cr	₹674 Cr	₹667 Cr	₹604 Cr	₹516 Cr	₹513 Cr	₹413 Cr	₹401 Cr	₹4 L
₹1073 Cr	₹970 Cr	₹765 Cr	₹807 Cr	₹673 Cr	₹620 Cr	₹639 Cr	₹448 Cr	₹3 L
₹2 Cr	₹71 Cr	₹302 Cr	₹309 Cr	₹512 Cr	₹116 Cr	₹10 Cr	₹2 Cr	₹70,000
₹39 Cr	₹42 Cr	₹92 Cr	₹72 Cr	₹6 Cr	₹26 Cr	₹21 Cr	₹6 Cr	₹0
₹237 Cr	₹100 Cr	₹91 Cr	₹577 Cr	₹420 Cr	₹348 Cr	₹78 Cr	₹74 Cr	₹80,000
₹2824 Cr	₹2335 Cr	₹1916 Cr	₹2369 Cr	₹2127 Cr	₹1623 Cr	₹1160 Cr	₹931 Cr	₹8 L
₹2141 Cr	₹1865 Cr	₹1477 Cr	₹1354 Cr	₹1381 Cr	₹178 Cr	-₹147 Cr	-₹450 Cr	-₹1 Cr
₹4157 Cr	₹3754 Cr	₹3528 Cr	₹3220 Cr	₹2834 Cr	₹2221 Cr	₹1726 Cr	₹1475 Cr	₹9 L
₹271	₹229	₹189	₹174	₹167	₹768	₹2,049	₹450	-₹1,398
₹271	₹229	₹189	₹174	₹167	₹70	₹37	₹8	-₹25

Cash Flow

Consolidated

Standalone

₹

Name

Profit Before Tax

Adjustment

Changes In working Capital

Cash Flow after changes in Working Capital

Cash Flow from Operating Activities

Cash Flow from Investing Activities

Cash Flow from Financing Activitie

Net Cash Inflow / Outflow

Opening Cash & Cash Equivalents

Cash & Cash Equivalent on Amalgamation / Take over / Merger

Closing Cash & Cash Equivalent

Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020	Mar 2019	Mar 2018
₹751 Cr	₹654 Cr	₹631 Cr	₹629 Cr	₹565 Cr	₹471 Cr	₹421 Cr	₹228 Cr	-₹1 L
₹116 Cr	₹81 Cr	₹79 Cr	₹45 Cr	₹71 Cr	₹133 Cr	₹57 Cr	-₹101 Cr	₹0
-₹129 Cr	-₹180 Cr	-₹134 Cr	-₹214 Cr	₹100 Cr	-₹108 Cr	-₹190 Cr	-₹93 Cr	-₹47 L
₹739 Cr	₹554 Cr	₹576 Cr	₹460 Cr	₹736 Cr	₹497 Cr	₹288 Cr	₹34 Cr	-₹48 L
₹565 Cr	₹392 Cr	₹414 Cr	₹306 Cr	₹598 Cr	₹388 Cr	₹195 Cr	₹10 Cr	-₹48 L
-₹570 Cr	-₹616 Cr	-₹116 Cr	-₹147 Cr	-₹122 Cr	-₹69 Cr	-₹51 Cr	-₹9 Cr	₹0
-₹64 Cr	-₹6 Cr	-₹279 Cr	-₹388 Cr	-₹79 Cr	-₹214 Cr	-₹137 Cr	₹54 L	₹49 L
-₹69 Cr	-₹230 Cr	₹18 Cr	-₹228 Cr	₹397 Cr	₹106 Cr	₹8 Cr	₹2 Cr	₹50,000
₹71 Cr	₹301 Cr	₹284 Cr	₹512 Cr	₹116 Cr	₹10 Cr	₹2 Cr	₹70,000	₹20,000
₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹8 L	₹0
₹2 Cr	₹71 Cr	₹301 Cr	₹284 Cr	₹512 Cr	₹116 Cr	₹10 Cr	₹2 Cr	₹70,000

Fundamental Ratios

Consolidated

Standalone

No results found

Alivus Life Sciences Share Price

1388.90-11.50 (-0.82%)

+32.60% past 1 Year

Shareholding summary

Promoters

74.87%

FII

5.54%

DII

1.53%

5.65%

Others

12.41%

Promoters

FII

DII

Others

Quarterly

Yearly

Shareholding Pattern

Quarterly

Yearly

Name

Promoters

FII

DII - Others

DII - MFs

Retail & Others

Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025
74.87%	74.87%	74.91%	74.91%	74.94%	74.99%
5.54%	5.30%	5.08%	6.84%	6.42%	6.57%
1.53%	1.64%	1.69%	1.60%	1.56%	1.60%
5.65%	5.63%	5.44%	3.87%	4.06%	3.59%
12.41%	12.56%	12.88%	12.78%	13.02%	13.25%

Bulk & block deals

Name

Icici Prudential Mutual Fund

Societe Generale

Bnp Paribas Arbitrage

Polar Capital Funds Plc-Healthcare Opportunities Fund

Nk Securities Research Private Limited

Deal Date	Action	Deal Value	Deal Price	Qty Traded	Deal Type	%Stake Traded	Exchange
04 Dec 2025	Purchase	84.38 Cr	₹870	9.70 L	Bulk	0.790015	BSE
25 Jan 2024	Purchase	12.09 Cr	₹799.55	1.51 L	Block	0.123134	BSE
25 Jan 2024	Sell	12.09 Cr	₹799.55	1.51 L	Block	0.123134	BSE
09 Aug 2021	Purchase	61.24 Cr	₹732.55	8.36 L	Bulk	0.68094	NSE
06 Aug 2021	Purchase	72.83 Cr	₹765.77	9.51 L	Bulk	0.774689	NSE
06 Aug 2021	Sell	72.87 Cr	₹766.12	9.51 L	Bulk	0.774689	NSE

Insider trading & SAST

Client name

Glenmark Pharmaceuticals Ltd

Glenn Mario Saldanha

Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Ltd

Nirma Ltd

Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Limited

Reported on	Client category	Action	%Stake traded	Holding % post deal	Deal value	Deal price	Qty traded	Deal period	Deal mode	Post transaction holding	Insider/SAST	Regulation type	Security type
24 Dec 2024	Promoter	Pledge	20	—	0	—	2.45 Cr	12 Mar 2024	Release	96,09,571	SAST	Reg31	—
22 Jul 2024	Promoter	Disposal	7.84	—	0	—	96.10 L	11 Jul 2024 - 12 Jul 2024	Offer For Sale	—	SAST	29(2)	—
17 Jul 2024	Promoter	Non disposal undertaking	—	—	0	—	96.10 L	04 Jul 2024	Release	0	SAST	Reg31	—
15 Jul 2024	Promoter Group	Disposal	0.006366	0	64.71 L	₹829.63	7.80 K	11 Jul 2024 - 12 Jul 2024	Others	0	Insider Trading	—	Equity Shares
15 Jul 2024	Promoter	Disposal	7.842806	0	798.30 Cr	₹830.73	96.10 L	11 Jul 2024 - 12 Jul 2024	Others	0	Insider Trading	—	Equity Shares
19 Mar 2024	Promoter	Disposal	20	7.84	0	—	2.45 Cr	12 Mar 2024	Off Market	96,09,571	SAST	29(2)	—
19 Mar 2024	Promoter	Acquisition	20	75	0	—	2.45 Cr	12 Mar 2024	Off Market	9,18,96,285	SAST	29(2)	—
14 Mar 2024	Promoter	Acquisition	55	55	0	—	6.74 Cr	05 Mar 2024 - 06 Mar 2024	Off Market	6,73,90,850	SAST	29(1)	—
14 Mar 2024	Promoter	Disposal	55	27.84	0	—	6.74 Cr	06 Mar 2024	Off Market	3,41,15,006	SAST	29(2)	—
13 Mar 2024	Promoter	Disposal	19.999996	7.84	1,465.40 Cr	₹597.99	2.45 Cr	12 Mar 2024	Off Market	96,09,571	Insider Trading	—	Equity Shares

Alivus Life Sciences Share Price

1388.90-11.50 (-0.82%)

+32.60% past 1 Year

Corporate Actions

Date

Type

Details

2026-09-01

Dividend

5.0

2025-09-01

Dividend

5.0

Company details

Registered office

Plot No. 170-172 Chandramouli Industrial Estate Mohol Bazarpeth Solapur Maharashtra PIN: 413213 Tel No: 02189 234456/234246 Fax No: NULL Email: [email protected] Internet: www.alivus.com

Registrars

Karvy Selenium Tower B, Plot 31-32Gachibowli,Financial District, NanakramgudaHyderabad – 500032Tel. No. 040 67161500Fax. No. 040 23001153E-mail: [email protected]: www.karvy.comToll Free No. of exclusive Call Centre:1-800-345001 Karvy Selenium Tower B, Plot 31-32 Gachibowli,Financial District Nanakramguda PIN: Tel No: 040 - 67162222/18003094001 Fax No: NULL Email: [email protected] Internet: www.kfintech.com

Management

Rudalf Corriea, Company Secretary & Compliance Officer

Hiren K Patel, Chairman

Yasir Rawjee, Managing Director & Chief Executive Officer

Kaushikbhai N Patel, Non Executive Independent Director

Manju Agarwal, Non Executive Independent Director

TL Easwar, Non Executive Independent Director

Savan Godiawala, Non Executive Independent Director

Vinod Naik, Whole Time Director - Technical Operations

Details

Alivus Life Sciences Share Price

Price Analysis

Share Price Live Stats

Share Market Cap & Key Ratios Overview

About

Stock Analysis (SWOT)

QVT

Peer Stocks

Alivus Life Sciences Share Price

Alivus Life Sciences Share Price

Financial overview

Compounded Sales Growth

Compounded Profit Growth

Stock Price CAGR

Return on Equity

Peer Comparison

Profit & Loss

Balance Sheet

Cash Flow

Fundamental Ratios

Alivus Life Sciences Share Price

Alivus Life Sciences Share Price

Oscillators

Moving averages

Alivus Life Sciences Share Price

Shareholding summary

Shareholding Pattern

Bulk & block deals

Insider trading & SAST

Alivus Life Sciences Share Price

Corporate Actions

Company details

Alivus Life Sciences Share Price

Corporate filings & documents

Announcements

Annual reports

Concalls & investor presentations

Alivus Life Sciences Share Price

News

Alivus Life Sciences to acquire 76 percent stake in Iqgen-X Pharma

Alivus Life Sciences Q1 EBITDA grows with strong margin expansion YoY

Alivus Life Sciences reports strong Q1 revenue growth of 6.7 percent YoY

Alivus Life Sciences Q1 net profit rises 33 percent year-on-year

Alivus Life Sciences to host Q1 FY27 earnings conference call on July 31

Alivus Life Sciences Reports Q4 EBITDA Growth to Rs 210 Crores, Margin Expands to 31.13%

Alivus Life Sciences Reports Strong Q4FY25 Earnings with Profit and Revenue Growth

Alivus Life Sciences reports Profit after tax of 162.66 Crores, in the March 2026 quarter

Alivus Life Sciences informs about disclosure

Alivus Life Sciences Fire Incident At Dahej: Production Recovery Timeline Announced

Alivus Life Sciences informs about updates

Fire at Alivus Life Sciences API Plant in Dahej Injures Three; Company Assessing Damages.

Alivus Life Sciences Management Guides for Additional CDMO Projects by Q1 FY27, Double-Digit Growth from FY28-29.

Alivus Life Sciences Solapur Plant Operations Timeline and Capacity Utilization Guidance

Alivus Life Sciences Revises FY26 Capex Guidance Down to INR450 Crores from INR600 Crores.

Alivus Life Sciences Raises EBITDA Margin Guidance to 30%-32% from 28%-30% on Efficiencies, Launches.

Alivus Life Sciences Guidance: High Single-Digit FY26 Revenue Growth Driven By Non-GPL And CDMO

Alivus Life Sciences - Quaterly Results

Alivus Life Sciences reports Profit after tax of 150.26 Crores, in the December 2025 quarter

Alivus Life Sciences Reports Q3 Revenue Growth to Rs 670 Crores, Up from Rs 642 Crores YoY.

Alivus Life Sciences Ltd Share Price Today

Alivus Life Sciences Quick Links

Other Stocks

Calculators

Brokerage Calculator

Stock Average Calculator

MTF Calculator

Margin Calculator

Span Margin Calculator